<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20131108015322N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-08</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of adding dexmedetomidine and fentanyl to lidocaine on the the quality of infraclavicular peripheral block in upper extremity orthopedic surgery</public_title>
      <acronym></acronym>
      <scientific_title>The Comparison of the effect of dexmedetomidine and fentanyl as adjuvant to lidocaine on the onset time and duration of ultrasound guided infraclavicular brachial plexus block in orthopedic upper limb surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65779</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: A simple randomization method by a table of random numbers is used to generate a random sequence of patients and participants are randomly assigned to one of the three study groups. To use the table of random numbers, the researcher first determines the direction of reading the numbers in the table. Then numbers 0-20 are considered for the control group, numbers 21-40 for intervention D group, and numbers 41-60 for intervention F group. Then the researcher puts the hand on one of the numbers and moves in the predetermined direction, records the numbers and assigns them to different groups. Each of the randomly assigned sequence numbers are recorded on a card and each card is placed in a sealed numbered envelope with the same card number. When the eligible participants enter the study, the envelopes are selected in order of their sequence and patients receive the intervention of the same group, Blinding description: Randomization and assignment of patients in each group is done by persons with no involvement in the trial. Participants, investigators, care provider and outcome assessors are unaware of the allocation of individuals in each study group.Since the participants, researchers and outcome assessors are unaware of the allocation of the study groups, and  the syringes containing the studied drugs are similar in terms of color and volume, this is a double blinded study.</study_design>
      <phase>3</phase>
      <hc_freetext>Improving the quality of infraclavicular brachial plexus block in terms of the onset and length of sensory and motor block and analgesic effect.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Receives 19 ml of lidocaine 1.5% with epinephrine 1:200000 + 1 ml of normal saline for infraclavicular block. Intervention 2: Fentanyl group: Receives 19 ml of lidocaine 1.5% with epinephrine 1:200000 + 1 ml containing 50 µg of fentanyl infraclavicular block. Intervention 3: Dexmedetomidine group: Receives 19 ml of lidocaine 1.5% + 1 ml containing 100 µg of dexmedetomidine for infraclavicular block.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shideh Dabir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Taleghani Hospital, Arabi St., Yemen St., Velenjak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717413</zip>
        <telephone>+98 21 2243 2595</telephone>
        <email>shdabir@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shideh dabir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Taleghani Hospital, Arabi St., Yemen St., Velenjak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717413</zip>
        <telephone>+98 21 2243 2595</telephone>
        <email>shdabir@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ASA class1 and 2
unilateral upper limb surgery
age 15-75 years
patient's acceptance</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>ASA class≥3
Allergy to local anesthetics
Age more than 75 yrs and less than 15 yrs
Coagulation disorders
Opium addiction
Infection at the block site
BMI &gt;30
liver or kidney failure
chronic use of painkillers and narcotics
patients who take narcotics before surgery
pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Receives 19 ml of lidocaine 1.5% with epinephrine 1:200000 + 1 ml of normal saline for infraclavicular block.</i_keyword>
      <i_keyword>Fentanyl group: Receives 19 ml of lidocaine 1.5% with epinephrine 1:200000 + 1 ml containing 50 µg of fentanyl infraclavicular block.</i_keyword>
      <i_keyword>Dexmedetomidine group: Receives 19 ml of lidocaine 1.5% + 1 ml containing 100 µg of dexmedetomidine for infraclavicular block.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The onset time of sensory block. Timepoint: After the end of local anesthetic injection every 5 minutes for 20 minutes. Method of measurement: Based on a 0-2 grading scale.</prim_outcome>
      <prim_outcome>The onset time of motor block. Timepoint: After the end of local anesthetic injection every 5 minutes for 20 minutes. Method of measurement: Based on modified Bromage scale 0-3.</prim_outcome>
      <prim_outcome>Duration of sensory block. Timepoint: After the end of local anesthetic injection every 5 minutes for 20 minutes. Method of measurement: Based on a 0-2 grading scale.</prim_outcome>
      <prim_outcome>Duration of motor block. Timepoint: After the end of local anesthetic injection every 5 minutes for 20 minutes. Method of measurement: Based on modified Bromage scale 0-3.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart rate. Timepoint: Before the block, 10, 20, and 30 minutes after the block, 5, 10, and 15 minutes after entering the recovery room, and 3, 12, and 24 hours after  operation. Method of measurement: Electrocardiogram, Pulse oximeter.</sec_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: Before the block, 10, 20, and 30 minutes after the block, 5, 10, and 15 minutes after entering the recovery room, and 3, 12, and 24 hours after  operation. Method of measurement: Noninvasive Blood pressure measurement method.</sec_outcome>
      <sec_outcome>Sedation level. Timepoint: Before the block, 10, 20, and 30 minutes after the block, 5, 10, and 15 minutes after entering the recovery room, and 3, 12, and 24 hours after  operation. Method of measurement: Sedation scale with a rating of 1-4.</sec_outcome>
      <sec_outcome>Pain severity. Timepoint: 10, 20 and 30 minutes after the start of the operation, 5, 10 and 15 minutes after entering the recovery and 3, 12 and 24 hours after operation. Method of measurement: A 5-point verbal rating scale (VRS) consisting of (0 =no pain, 4=unbearable pain).</sec_outcome>
      <sec_outcome>Total number of patient’s requests for systemic analgesics. Timepoint: In the first 24 hours after operation. Method of measurement: Recording the number of requests for analgesic.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-26</approval_date>
        <contact_name>Research Ethics Committee of shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Building no. 2, 6th floor, Office of Research Affairs, Shahid Chamran Highway, Yemen St., Arabi St., next to Taleghani Hospital, Shahid Beheshti University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
